Company Profile
One of the world's largest pharmaceutical companies, Roche sells its products in over 100 countries. Roche's prescription drugs include cancer therapies MabThera/Rituxan and Avastin, Perjeta and Kadcyla for HER2-positive breast cancer, idiopathic pulmonary fibrosis drug Esbriet, macular degeneration therapy Lucentis, and Tamiflu, which is used for infectious diseases. The company markets many of its bestsellers through California-based subsidiary Genentech and Japanese affiliate Chugai Pharmaceutical. Roche's diagnostics arm offers clinical lab supplies, genetic tests, diabetes monitoring supplies, and point-of-care diagnostics for health care providers. Roche records among the world's highest pharmaceutical R&D spend annually and generates majority of sales from North America.
Roche Holding AG
One of the world's largest pharmaceutical companies, Roche sells its products in over 100 countries. Roche's prescription drugs include cancer therapies MabThera/Rituxan and Avastin, Perjeta and Kadcyla for HER2-positive breast cancer, idiopathic pulmonary fibrosis drug Esbriet, macular degeneration therapy Lucentis, and Tamiflu, which is used for infectious diseases. The company markets many of its bestsellers through California-based subsidiary Genentech and Japanese affiliate Chugai Pharmaceutical. Roche's diagnostics arm offers clinical lab supplies, genetic tests, diabetes monitoring supplies, and point-of-care diagnostics for health care providers. Roche records among the world's highest pharmaceutical R&D spend annually and generates majority of sales from North America.
Financial Statements
Financial data as of December 31, 2019 (12 month period) in USD
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Cash Flow (mil) | 2019 | 2018 | 2017 |
---|---|---|---|
Net Operating Cash | $22,559.36 | $20,134.62 | $18,164.39 |
Net Investing Cash | -$8,701.25 | -$7,251.04 | -$6,509.31 |
Net Financing Cash | -$14,283.39 | -$10,774.27 | -$11,201.57 |
Net Change in Cash | -$425.29 | $2,109.3 | $453.51 |
Cash at Beginning of Period | $6,733.04 | $4,755.76 | $4,195.43 |
Cash at End of Period | $6,122.32 | $6,733.04 | $4,755.76 |
Capital Expenditure | -$4,934.13 | -$4,960.34 | -$4,245.82 |
Assets (mil) | 2019 | 2018 | 2017 |
---|---|---|---|
Current Assets | |||
Cash and Cash Equivalents | $6,122.32 | $6,733.04 | $4,755.76 |
Accounts Receivable | $10,901.25 | $10,201.85 | $9,930.75 |
Inventories | $6,102.16 | $6,672.57 | $7,464.69 |
Other Current Assets | $8,371.7 | $8,887.69 | $9,666.71 |
Asset Summary | |||
TOTAL CURRENT ASSETS | $31,497.44 | $32,495.15 | $31,817.91 |
Tangible Fixed Assets | $23,499.62 | $21,987.94 | $21,074.88 |
Intangible Assets | $8,423.1 | $9,418.8 | $8,433.18 |
Total Assets | $83,738.2 | $79,128.57 | $77,273.23 |
Liabilities (mil) | 2019 | 2018 | 2017 |
---|---|---|---|
Current Liabilities | |||
Accounts Payable | $3,200.74 | $2,869.18 | $2,807.7 |
Short-Term Debt | $1,708.2 | $2,713.98 | $3,145.31 |
Other Current Liabilities | $19,397.92 | $17,629.25 | $16,379.59 |
Liability Summary | |||
Total Current Liabilities | $24,306.86 | $23,212.4 | $22,332.6 |
Long-Term Debt | $12,766.67 | $16,202.22 | $15,962.37 |
Other Long-Term Liabilities | $93.72 | $158.22 | $120.93 |
Total Liabilities | $47,591.83 | $48,526.05 | $48,040.29 |
Stakeholder's Equity (mil) | 2019 | 2018 | 2017 |
---|---|---|---|
Equity | |||
Common Stock | $161.25 | $161.25 | $161.25 |
Retained Earnings | $40,839.64 | $35,207.11 | $33,525.11 |
Equity Summary | |||
Total Equity | $33,002.07 | $27,837.15 | $26,646.95 |
Shares Outstanding | 855,756,455 | 853,849,723 | 853,849,723 |
Credit Reports
See detailed business credit reports on other businesses or your own.
Competitor Profiles
See detailed profiles for insights and prospects on this company's top competitors.
Company Snapshot
Essential information for a successful call
-
EMPLOYEES (All Sites)
146
- ASSETS (MIL USD) 83,738
-
REVENUE (MIL USD)
61,944.76
- TICKER SYMBOL ROG
- Year Started 1896
- Incorporated 1995
- FISCAL YEAR END DEC
- SALES GROWTH % 8.12%
- NET INCOME GROWTH 28.54%
Get in Touch with 24 Principals*
-
Severin Anton SchwanManaging Director and Member of the Board of Directors and Authorised Signatory
-
Christoph FranzChairman of the Board
-
Andreas HoffmannVice Chairman of the Board
-
Claudia SüssmuthMember of the Board of Directors
Want more contacts like these available directly in your inbox? Install D&B Email IQ to access your next prospects!
See full contact details